PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/700,417 November 4, 2003 Filing Date TRANSMITTAL First Named Inventor Alfred Binggeli **FORM** Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21477

Total Number of Pages in This Submission									
ENCLOSURES (Check all that apply)									
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks After Allowance communication to Group (Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Cited art								
SIGNA	ATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm or Individual name Frank Hoffmai	n								
Signature	DOF LOND								
Date 5/4/04	5/4/04								
CERTIFICATE OF TRANSMISSION/MAILING									

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name Frank Hoffman Date 5/4/04 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT APPLICATION



In re Patent Application

Binggeli et al

Group:

Serial No. 10/700,417, filed November 4, 2003

Examiner:

For: NOVEL SUBSTITUTED OXAZOLE DERIVATIVES

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110 May 4, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

That each item of information contained in the enclosed information disclosure Χ_ statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this information disclosure statement.

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney for Applicar Frank Hoffman

(Reg. No. 26468)

340 Kingsland Street

Nutley, NJ 07110

Telephone: (973) 235-3916 Telefax: (973) 235-2363



E UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Binggeli et al

Group:

Serial No. 10/700,417, filed November 4, 2003

Examiner:

For: NOVEL SUBSTITUTED OXAZOLE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 May 4, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B5 listed on Form PTO-1449 are enclosed.

Enclosed is a Search Report, dated March 2, 2004, which was issued by the European Patent Office in PCT/EP 03/12189 application corresponding to the captioned application. The Search Report lists Documents B1-B5.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/700,417 Filed: November 4, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due.

Respectfully submitted,

Attorney for Applican

Frank Hoffman (Reg. No. 26468)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-3916

Telefax: (973) 235-2363

141890

Substitute for form 1449A/PTO				$\overline{}$	Complete if Known			
INFORMATION DISOLOGURE STATEMENT BY APPLICANT				EE	Application Number 10/700,417			
				2004	Filing Date		November 4, 2003	
(Use several sheets if necessary) 0 6 2004					First Name Inventor	Alfred B	Alfred Binggeli	
(Use several sheets if necessary)				إنبع	Group Art Unit			
Sheet 1 of 1				6/	Examiner Name			
Sheet 1	et 1 of 1 TRADEMANTE			Attorney Docket Number 21477				
				7101 1 1117	ENT DOCUMENTS			
	Cita	U.S. Patent Document		ent	Name of Patentee or App	licant of	of Date of Publication of	
Examiner Initials'	Cite No.'	Number Kind Code ² (if known)			Cited Document		Cited document	
							MM-DD-YYYY	
				_				
			·····					
, , , , , , , , , , , ,				 				
			·					
				ļ				
					PATENT DOCUMENTS		07.111	T mx
	Cite No.'	Foreign Patent Document			Name of Patentee or		Date of Publication of Cited Document	
Examiner Initials'		Office ³	Number*	Kind Co	Applicant of Cited Document		MM-DD-YYYY	
illitials		WOO	1/10702	(if known)	Pfizer Inc.		12-26-1991	
-	B1	WO 91/19702 WO 02/16331 WO 02/16332			Eli Lilly and Comp		02-28-2002	
	B2						02-28-2002	
	B3				Eli Lilly and Comp			
	B4	B4 WO 00/66572			Dr. Reddy's Resear	rcn 11	11-09-2000	
	,			Foundation		10.00 1000		
	B5	WO 9	8/57636		SmithKline Beecha	m 12	2-23-1998	┼
								╄
								<u> </u>
-								
								<u>L</u>
		1						
		+						
Examiner	ļ	Date Co	onsidered					-
Signature) Date of					formance and not considered. I	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Benter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.